The influence of tightening regulations on patients with new psychoactive substance‐related disorders in Japan
Sign Up to like & getrecommendations! Published in 2018 at "Neuropsychopharmacology Reports"
DOI: 10.1002/npr2.12035
Abstract: This study aimed to investigate the influence of tightened regulations on new psychoactive substances in patients with disorders related to these drugs in Japan. read more here.
Keywords: influence tightening; regulations patients; tightening regulations; patients new ... See more keywords
Adrenal insufficiency in critical patients: New ethiopathogenic concepts and therapeutic implications.
Sign Up to like & getrecommendations! Published in 2017 at "Endocrinologia, diabetes y nutricion"
DOI: 10.1016/j.endinu.2017.09.004
Abstract: Recently, there have been advances in understanding of the changes that occur in the hypothalamic-pituitary-adrenal axis during the different stages of critical disease. Such advances have led to a paradigm change, so that the aforementioned… read more here.
Keywords: adrenal insufficiency; patients new; insufficiency critical; new ethiopathogenic ... See more keywords
Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.
Sign Up to like & getrecommendations! Published in 2018 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2017.10.010
Abstract: BACKGROUND Fibroblast growth factor (FGF) 23 is a hormone that increases urinary phosphate excretion and regulates renal sodium reabsorption and plasma volume. We studied the role of plasma FGF23 in therapy optimization and outcomes in… read more here.
Keywords: fgf23; volume; patients new; fibroblast growth ... See more keywords
EARLY MORTALITY IN PATIENTS WITH NEW ONSET ATRIAL FIBRILLATION: RESULTS FROM THE GARFIELD-AF REGISTRY
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(17)33704-x
Abstract: Background: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is a non-interventional study which, like Framingham Heart Study, provides a record of early events from the time of diagnosis of nonvalvular atrial fibrillation (AF). Patients… read more here.
Keywords: atrial fibrillation; fibrillation; early mortality; patients new ... See more keywords
Gut microbiome could predict drug response in RA
Sign Up to like & getrecommendations! Published in 2021 at "Nature Reviews Rheumatology"
DOI: 10.1038/s41584-021-00582-6
Abstract: volume 17 | mARCH 2021 | 129 which is well known to vary in patients with rheumatoid arthritis (RA). “our analysis revealed that in patients with new-onset, treatment naive RA there are significant associations between… read more here.
Keywords: response; patients new; microbiome; gut microbiome ... See more keywords
Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
Sign Up to like & getrecommendations! Published in 2022 at "Renal Failure"
DOI: 10.1080/0886022x.2022.2050754
Abstract: Abstract Background Both early correction of anemia and preserving residual renal function (RRF) are reported to improve patient survival. The aim of this study was to explore the efficacy and safety of Roxadustat for treatment… read more here.
Keywords: roxadustat group; group; peritoneal dialysis; patients new ... See more keywords
P427Influence of ranolazine on cardioversion rate in patients with new onset atrial fibrillation and ischemic disease of the heart
Sign Up to like & getrecommendations! Published in 2020 at "Europace"
DOI: 10.1093/europace/euaa162.337
Abstract: Ranolazine is a piperazine derivative, mainly used as antianginal drug in patients with ischemic disease of the heart (IDH). Despite its antianginal effect, it has an antiarrhythmic effect by inhibiting of late sodium and rapid… read more here.
Keywords: ischemic disease; patients new; group; disease heart ... See more keywords
A Randomized Controlled Trial of Anti-TNF α Bio-similar Adalimumab vs. Prednisolone in the Management of Leprosy Patients with New Type 1 Lepra Reaction
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.1805
Abstract: Abstract Background Leprosy Type 1 (T1R) reactions are immune-mediated events leading to nerve damage and preventable disability affecting hands, feet and eyes. TNF-α is the main inflammatory cytokine associated. Type 1 Reactions are treated with… read more here.
Keywords: randomized controlled; tnf; patients new; prednisolone ... See more keywords
Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus
Sign Up to like & getrecommendations! Published in 2017 at "Medicine"
DOI: 10.1097/md.0000000000007507
Abstract: Abstract Early type 2 diabetes mellitus (DM) may only require lifestyle modifications for glycemic control without the need for oral hypoglycemic agents (OHAs). Metformin is believed to improve cardiovascular outcomes in patients with DM, and… read more here.
Keywords: new diagnosis; patients new; type diabetes; diabetes mellitus ... See more keywords
Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15258
Abstract: The COVID‐19 pandemic is a global public health emergency and patients with diabetes mellitus (DM) are disproportionately affected, exhibiting more severe outcomes. Recent studies have shown that metformin is associated with improved outcomes in patients… read more here.
Keywords: covid patients; metformin affect; patients new; diabetes mellitus ... See more keywords
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-221126
Abstract: Background Polymyalgia rheumatica is the second most common inflammatory rheumatic disease of people >50 years. Glucocorticoid therapy is highly effective, but many patients require treatment for several years. Effective glucocorticoid sparing agents are still needed.… read more here.
Keywords: polymyalgia; polymyalgia rheumatica; trial; new onset ... See more keywords